Gary Raskob to Incidence
This is a "connection" page, showing publications Gary Raskob has written about Incidence.
Connection Strength
1.145
-
Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. J Thromb Haemost. 2022 10; 20(10):2366-2378.
Score: 0.180
-
Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma. Thromb Haemost. 2021 Jun; 121(6):816-825.
Score: 0.161
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.
Score: 0.146
-
The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10.
Score: 0.113
-
The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18.
Score: 0.109
-
Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71.
Score: 0.105
-
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9.
Score: 0.076
-
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104.
Score: 0.064
-
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211053316.
Score: 0.040
-
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thromb Haemost. 2020 Mar; 120(3):515-524.
Score: 0.038
-
Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul; 118(7):1270-1278.
Score: 0.034
-
Clinical decisions in idiopathic thrombocytopenic purpura. Hosp Pract (1995). 1997 Sep 15; 32(9):159-60, 163-6, 169-70, passim.
Score: 0.032
-
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37.
Score: 0.019
-
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87.
Score: 0.018
-
Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S.
Score: 0.010